Stoke Therapeutics, Inc.
- STOK
- NASDAQ
- Biotechnology
- Antisense Oligonucleotide Therapies
- Genetic Disorder Treatments
$24.69
Today +2.15%Quote Oct 19, 2026, 05:39 PM UTC
−16.45%over the last month
Max drawdown −22.9%From 1-month high −17.2%3 months −12.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Stoke Therapeutics
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
170
Founded
2014
Market value
$1.59B
Quote Oct 19
Floor
$24.68
0.0% below price
Resistance
$26.37
6.8% above price
Price vs analyst targets
16 analysts
Lowest target
$44.00Highest target
$58.00
$44.00Highest target
$58.00
- Price $24.69
- Average target $51.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 107% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about STOKPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free